

Analysis of dietary vitamin C intake levels and the risk of hyperuricemia and gout based on cross-sectional studies and bi-directional Mendelian randomisation

1 Zi-Ning Peng^{1†}, Xing-Qiang Wang^{2,3†}, Qian Deng¹, Wei-Tian Yan¹, Wei-Qing Zhao⁴, Yong-Bin Pu²,
2 Nian Liu^{1,3*}, Ling-Li Gu^{2*}, Jiang-Yun Peng^{2,3*}

3 ¹First school of clinical medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan,
4 650500, PR China

5 ²Department of Rheumatology, The No.1 Affiliated Hospital of Yunnan University of Chinese
6 Medicine, Kunming, Yunnan, 650021, PR China

7 ³Yunnan Provincial Clinical Medicine Research Center of rheumatism in TCM, Yunnan provincial
8 hospital of traditional Chinese medicine, Yunnan, 650021, PR China

9 ⁴Department of Rheumatology and Immunology, The First People's Hospital of Yunnan Province
10 and The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan,
11 650034, PR China

12
13 † **Co-first Author**

14 Zi-Ning Peng

15 E-mail: pzn2019@126.com

16 Xing-Qiang Wang

17 E-mail: ouyangfengyangguo@163.com

18 * **Correspondence:**

19 Nian Liu

20 E-mail: liunian8917@163.com

21 Jiang-Yun Peng

22 E-mail: pengjiangyun@126.com

23 Ling-Li Gu

24 E-mail: guyuxin82@126.com

25 **Preferred language:** British English

26 **Number of words:** 3,929

27 **Number of figures and tables:** 4 figures and 7 tables

28 **Running title:** Vitamin C and hyperuricemia/gout risk

29 **Keywords:** vitamin C, NHANES, Mendelian randomisation, hyperuricemia, gout, cross-sectional
30 study

31 **Abstract**

32 **Background:** Vitamin C, a common antioxidant, may be useful for treating hyperuricemia and gout.
33 The aim of this study was to investigate the risk association between dietary vitamin C intake and
34 hyperuricemia/gout and to test for causality using the bi-directional Mendelian randomisation
35 method.

36 **Methods:** Cross-sectional studies were selected from the National Health and Nutrition
37 Examination Survey from 2007–2018 to assess the association between dietary vitamin C intake
38 and the risk of hyperuricemia/gout, according to multivariate logistic regression modelling. Bi-
39 directional Mendelian randomisation studies were conducted using genetic data from large-scale
40 genome-wide association surveys of supplemental vitamin C, pharmacological vitamin C, and
41 ascorbic acid intake and hyperuricemia/gout; these aimed to infer causal relationships between
42 vitamin C and hyperuricemia/gout. Inverse variance weighting was used as the primary method of
43 Mendelian randomisation analysis. A series of sensitivity analyses were used to assess multiplicity.
44 **Results:** The cross-sectional study included 17.52% and 82.48% patients with and without
45 hyperuricemia, respectively, as well as 2.67% and 97.33% patients with and without gout,
46 respectively. In the model correcting for all covariates, the association between vitamin C intake
47 and the risk of hyperuricemia/gout was stable, and the risk of hyperuricemia was generally lower
48 in patients who consumed >111.75 mg vitamin C than in other patients when comparing three
49 models with different moderators. Restricted cubic spline scores indicated that vitamin C intake
50 recommendations of 75–525 mg and 75–225 mg were effective for targeting hyperuricemia and
51 gout, respectively. In inverse variance weighting in the Mendelian randomisation analysis, the
52 amount of vitamin C absorbed was negatively associated with hyperuricemia (OR = 0.985, 95% CI
53 = 0.973–0.997, $p = 0.015$), and supplemental vitamin C was negatively associated with gout (OR =
54 0.857, 95% CI = 0.797–0.921, $p < 0.001$); sensitivity analysis yielded consistent results. Reverse
55 Mendelian randomisation analysis showed that vitamin C had no reverse causal relationship with
56 hyperuricemia and gout.
57 **Conclusion:** We hypothesise that a dietary vitamin C intake of 75–525 mg or 75–225 mg may
58 reduce the risk of hyperuricemia and gout, respectively. Further research with larger samples is
59 required to confirm this.

60 **1 Introduction**

61 Gout has long been known as the “disease of kings” because of the disproportion rates of gout in
62 royal families (1). In modern society, hyperuricemia (HUA) and other musculoskeletal diseases are
63 common medical issues due to improvements in living standards (2). Cases of HUA and gout are
64 increasing globally, particularly in higher-income, developed economies. Although current
65 epidemiological data are incomplete, approximately one in five people are affected by increased
66 uric acid levels and their effects; the prevalence of HUA and gout are approximately 20% and 2.6%,
67 respectively (3, 4).
68 Generally, gout begins as asymptomatic HUA, gradually developing into clinical symptoms
69 accompanied by uric acid crystal deposits in the joint cavities, and finally advancing to a diagnosis
70 of gout. This continuous process produces a series of complications (5). Persistent HUA can easily
71 trigger end-stage diseases, resulting in increased mortality. Therefore, controlling high uric acid
72 levels is crucial in determining treatment opportunities for gout. Epidemiological research shows
73 that behavioural factors, especially dietary factors, affect uric acid metabolism. Although several
74 anti-gout medications, such as febuxostat and colchicine, have been approved for use by the US
75 Food and Drug Administration in recent years, these medications have significant adverse effects,
76 including renal and hepatic failure and cardiotoxicity (6). Therefore, vitamin C (VC) has piqued the
77 interest of researchers as a common antioxidant.
78 VC, also known as ascorbic acid, plays a pleiotropic role in living organisms. In 1932, Hungarian

79 biologist Albert Szent-Györgyi first discovered VC and used it to regulate different biological
80 processes (7). VC possesses bi-directional properties, acting as both an antioxidant and a pro-
81 oxidant. Additionally, it exhibits properties that are related to the immune system. These
82 characteristics of VC can aid in reducing HUA (8). Although dietary approaches appear to play an
83 important role in preventing gout attacks or the onset of the disease, a comprehensive understanding
84 of the interaction between uric acid and VC in the human body remains insufficient.
85 In HUA- or gout-related research, it is already very common to observe the protective properties of
86 VC. For example, research shows that dietary and supplemental VC intake are negatively correlated
87 with HUA risk (9). However, focusing solely on HUA is insufficient; therefore, our research also
88 included participants with gout. In addition, the National Health and Nutrition Examination Survey
89 (NHANES) 2007-2018 was used to add more data compared to previous research, and quartiles of
90 dietary VC were observed. Supplemental VC was not considered as part of the overall dietary intake
91 to avoid potential disruptions in our analysis; therefore, the effects of supplemental VC were
92 excluded from our study.
93 Mendelian randomisation (MR) is an epidemiological method that uses genetic variation as an
94 instrumental variable (IV) to represent exposure to a variable of interest. It is also used to investigate
95 the effect of exposure on specific outcomes (10). In the present study, we investigate the underlying
96 causal relationship between VC and gout/HUA. We performed MR analysis using genome-wide
97 association study (GWAS) data. MR is the ideal tool for studying immune diseases because when
98 exposed to external environmental factors, genetic variables can affect life expectancy. We used the
99 bi-directional MR method to analyse and predict the causal effects of VC on gout and HUA, which
100 helped mitigate bias from dietary questionnaires in the NHANES database, thereby enhancing the
101 reliability of the results.

102 **2 Material and Methods**

103 This study consisted of two parts. In the first part, we conducted a study using data from a large
104 sample of the NHANES to explore the association between VC intake and HUA/gout. Due to
105 questionnaire bias in the NHANES database, we supplemented the second part with a bi-directional
106 MR analysis utilising GWAS pooled statistics to reduce bias and avoid reverse causality and
107 assessed the causal effects of VC intake on HUA and gout. The overall study design is shown in
108 Figure 1.

109 **2.1 Cross-sectional Study**

110 **2.1.1 Study Population**

111 NHANES examined a nationally representative sample of the civilian non-institutionalised
112 population of the USA of all ages using a complex multistage probability design. We used the most
113 recent NHANES database containing data from six cycles (2007–2018) (n = 59,842). Figure 1A
114 shows the NHANES 2007–2018 sample selection flowchart. Following a home interview,
115 participants were invited to complete additional questionnaires, undergo testing, and provide blood
116 and other biospecimens in a mobile examination centre. The National Centre for Health Statistics
117 Research Ethics Review Board approved NHANES, and all participants provided informed consent
118 for the home interview and tests at the mobile examination centre. There were 28,227 participants
119 aged 18 years or older who were eligible for the dietary questionnaire in this survey. Individuals

120 who did not provide a blood uric acid specimen (n = 1,455), those who currently or previously had
121 a tumour (self-reported) (n = 3,801), and those taking uric acid-lowering medications (allopurinol,
122 febuxostat, or probenecid) that interfered with the investigation (n = 291) were excluded, and the
123 remaining 22,680 individuals were enrolled in our next step of analysis.

124 **2.1.2 Dietary VC Intake**

125 Dietary VC intake was assessed using 24 h recall. Relying on the US Department of Agriculture
126 Food and Nutritional Database (2007–2018) to determine the nutrient composition, supplied energy,
127 and other components of diet and fluids, all participants underwent two 24 h recalls. The interviews
128 included all types of food and fluids consumed. Thereafter, we analysed the average VC intake,
129 including VC from all meals consumed by the participants, while excluding VC from supplements.

130 **2.1.3 HUA and Gout Diagnosis**

131 Serum concentrations of uric acid were measured using the Beckman UniCel® DxC 800 Synchron
132 or Beckman Synchron LX20 (Beckman Coulter, Inc., Brea, CA, United States) after the uric acid
133 was oxidised by uricase to form allantoin and H₂O₂. HUA was diagnosed when uric acid levels
134 were ≥ 420 $\mu\text{mol/l}$ (7 mg/dL) in men and ≥ 360 $\mu\text{mol/l}$ (6 mg/dL) in women (11). Gout flares were
135 defined by self-assessment in a questionnaire.

136 **2.1.4 Covariates**

137 Demographic characteristics included age, sex, race (Hispanic American, non-Hispanic white, non-
138 Hispanic black, and other races), marital status (married, widowed, divorced, and unmarried), and
139 education level (less than high school, high school graduate, and equal to college and above). Other
140 covariates included smoking status (never, ex-smoker, and current persistent smoker), alcohol use
141 (defined as at least one drink per month in the last year), poverty level, body mass index, and waist
142 circumference. History of cardiovascular disease, hypertension, hyperlipidaemia, kidney stones,
143 and diabetes mellitus were defined as self-reported medical diagnoses. Glomerular filtration rate
144 was used to assess renal function, which was calculated using the CKD-EPI creatinine equation
145 (12). Blood specimens were processed, stored, and shipped to their respective laboratories for
146 analysis, including creatinine, glucose, cholesterol, triglyceride, direct cholesterol, and uric acid
147 analysis.

148 **2.1.5 Statistical Analysis**

149 R version 4.2.2 was used for all analyses. Counts and proportions were used for categorical
150 variables, whereas means and standard deviations were used for continuous data, and sampling
151 weights were considered for all analyses. For two-tailed tests, $p < 0.05$ was considered statistically
152 significant. Based on VC intake quartiles, subjects were categorised into Q1 (0–29.1 mg), Q2 (29.1–
153 61.0 mg), Q3 (61.0–111.75 mg), and Q4 (>111.75 mg), and descriptive statistics were used to
154 analyse the characteristics of the participants. Categorical variables were compared using the Chi-
155 square test, and continuous variables were compared using ANOVAs or the Kruskal–Wallis H test.
156 In this study, three models were produced: Model 1 included all variables, Model 2 corrected for
157 some demographically relevant variables, and Model 3 corrected for all covariates. Logistic
158 regression models and restricted cubic spline analyses were carried out to assess the correlation
159 between dietary VC intake with the risk of developing gout and HUA.

160 **2.2 Bi-directional MR Study**

161 **2.2.1 Study Design**

162 The overall design of the MR study is shown in Figure 1B. To obtain valid causal effect estimates,
163 IVs in the forward MR model need to meet the following three conditional assumptions: 1) genetic
164 variations are significantly associated with VC intake levels; 2) genetic variations are not associated
165 with other confounders; and 3) they affect gout or HUA only through the VC intake levels. Inverse
166 MR model IVs need to meet the following three conditional assumptions: 1) genetic variations are
167 significantly associated with gout or HUA; 2) genetic variations are not associated with other
168 confounders; and 3) they affect VC intake levels only through gout or HUA.

169 **2.2.2 Data Sources and Genetic Tools**

170 Genetic tools were mainly derived from the latest GWAS meta-analysis, i.e. GWAS summary data
171 (13). GWAS is a genome-wide test of polymorphic genetic variants (markers) in multiple
172 individuals, enabling researchers to obtain genotypes for statistical analysis at the population level.
173 We used GWAS to identify sequence variants, known as single nucleotide polymorphisms (SNPs),
174 present on a genome-wide scale in humans. From this, we screened for SNPs associated with HUA,
175 gout, and VC intake (14). HUA and gout data were obtained from the EBI database in the GWAS
176 database, and VC data were obtained from the UKB database. Due to the lack of GWAS data on
177 dietary VC, for the sake of completeness, we used all VC-related data from the UKB database for
178 MR analysis, including data on “supplements: vitamin C”, “medication: vitamin C” and “vitamin
179 C absorbed”. The specific data examined in this study are shown in Supplementary Table 1.

180 **2.2.3 Statistical Analysis**

181 MR analysis was mainly performed using inverse variance weighting (IVW)-random effects and
182 IVW-fixed effects models. All statistical analyses were performed using “two sample MR” in R
183 software. In addition, weighted median and MR-Egger regression were applied to supplement the
184 analyses. Heterogeneity and pleiotropy among the selected SNPs were assessed using Cochrane Q-
185 analysis and MR-Egger intercepts. Leave-one-out analysis was performed to test whether the
186 estimates were driven by individual SNPs. Statistical power and F-statistic computational
187 measurements ensured sufficient statistical efficacy to avoid weak IV bias. Power calculation was
188 performed using the online tool mRnd¹ and the IV was deleted when the IV strength measure F-
189 statistic was <10 to minimise the chance of MR analysis bias. Finally, reverse MR was applied to
190 test for the presence of reverse causal links.

191 **3 Results**

192 **3.1 Cross-sectional Study**

193 **3.1.1 Basic Characteristics of Study Participants**

194 Tables 1 and 2 summarise the overall characteristics of the study participants, that is, whether they
195 had HUA and gout, respectively. Among the participants, 17.52% had HUA and 82.48% did not
196 have HUA, whereas 2.67% had gout and 97.33% did not have gout. Separate analyses were
197 performed according to sex, race, marital status, education, alcohol consumption, smoking status,
198 hypertension, hyperlipidaemia, and diabetes, in relation to the presence of HUA or gout. Table 1

¹<https://shiny.cnsgenomics.com/mRnd/>

199 shows that, with the exception of alcohol consumption ($p = 0.8$) and poverty level ($p = 0.2$), all
200 other variables exhibit statistically significant differences ($p < 0.001$) between individuals with
201 HUA and those with kidney stones ($p = 0.006$). Table 2 shows that, in addition to education level
202 ($p = 0.4$), poverty level ($p = 0.4$), and cholesterol ($p = 0.6$), race ($p = 0.014$), alcohol consumption
203 ($p = 0.006$), and VC ($p = 0.003$) showed statistical significance with regard to having gout.
204 Furthermore, the other covariates showed statistically significant differences with regard to having
205 gout ($p < 0.001$). The overall basic characteristics indicated that the prevalence of HUA and gout
206 was higher in men than in women, and that patients with HUA and gout had lower VC intake than
207 patients without these diseases.

208 **3.1.2 Relationship Between HUA/Gout and VC Intake Level**

209 Table 3 demonstrates the relationship between HUA/gout and VC intake level quartile. Logistic
210 regression showed that Model 1, which did not correct for any variables, had the weakest correlation
211 between VC intake level and the risk of HUA/gout. Model 2 increased the association between VC
212 intake and the risk of HUA/gout; it controlled for age, sex, race, marital status, education, alcohol
213 consumption, and smoking-related demographic variables. Model 3 corrected all covariates. After
214 correction, the correlation between VC intake and the risk of HUA and gout in Model 3 was stable.
215 Additionally, in these three models, VC intake and the risk of HUA in Q4 were generally lower
216 than in Q1–3. After correcting for covariates, the protective effects of VC became increasingly
217 evident from Model 1 to Model 3.

218 **3.1.3 Dose–response Relationship Between HUA/Gout and VC Intake**

219 After completely adjusting for confounding factors and correcting for all covariates, restricted cubic
220 spline analysis was performed for HUA/gout and VC intake, respectively. This showed that VC
221 intake had a non-linear relationship with both HUA ($p < 0.0001$) and gout ($p = 0.001$) in participants
222 affected by either (Figure 2). Among these participants, a VC intake of 75–525 mg and 75–225 mg
223 can effectively target HUA and gout, respectively.

224 **3.2 Bi-directional MR Study**

225 **3.2.1 MR Analysis Using IVs Based on GWAS**

226 SNPs were selected according to the following criteria: SNPs related to confounding factors
227 between VC and HUA were excluded (e.g. those related to haemolysis, diabetes, cholesterol,
228 lymphoma, chemotherapy, alcohol, metabolic syndromes, metabolism, and gout); SNPs related to
229 confounding factors between VC and gout were excluded (e.g. those related to diabetes, cholesterol,
230 alcohol, metabolic syndromes, metabolism, uric acid levels, HUA, and hypertension); SNPs related
231 to the results; and SNPs that were not present in the results. For MR analysis, we selected all SNPs
232 with critical values of $p < 1 \times 10^{-5}$ related to HUA/gout–VC absorbates; the remaining selection (p
233 $< 1 \times 10^{-6}$) was used as an IV to increase the number of available SNPs and to facilitate subsequent
234 sensitivity analyses.

235 We assessed the causal relationship between VC and HUA/gout based on different IVs (Table 4).
236 The MR results show a causal relationship between VC absorbates and HUA; the MR IVW results
237 show a negative correlation between VC absorbates and HUA (OR = 0.985, 95% CI = 0.973–0.997,
238 $p = 0.015$). The results of all three other methods, MR-Egger, weighted median, and weighted mode,
239 were statistically significant ($p < 0.05$), consistent with the IVW results. Figure 3A shows a

240 scatterplot of the correlation between SNPs and HUA, as well as between SNPs and VC absorbates.
241 Figure 3B shows a forest plot for each SNP in VC absorbate–HUA estimation, suggesting the
242 magnitude of the MR effects of VC on HUA. As shown in Table 4, no statistically significant
243 relationship was observed between supplemental VC or pharmacological VC and HUA in this MR
244 analysis.

245 In addition, the MR IVW analysis results show a causal relationship between supplemental VC and
246 gout (OR = 0.857, 95% CI = 0.797–0.921, $p < 0.001$), supported by the weighted median method
247 ($p < 0.05$); correlation scatter plots and forest plots indicate the magnitude of the MR effect of VC
248 on gout, as shown in Figure 4A and B. However, there was no statistically significant relationship
249 between supplemental VC absorbates or pharmacological VC and gout in the MR analysis, as
250 shown in Table 4.

251 **3.2.2 MR Sensitivity Analysis**

252 We estimated the stability of the MR results using sensitivity analysis, as shown in Table 5. In the
253 analysis of VC absorbates versus HUA, Cochran’s Q test showed that there was slight heterogeneity
254 in the MR-Egger analysis ($p = 0.049$). The MR-Egger intercept test indicated that the MR analyses
255 were not affected by horizontal pleiotropy ($p > 0.05$). Leave-one-out sensitivity analysis confirmed
256 the robustness of the MR results, and the absence of major SNPs (Figure 3C) greatly affected the
257 results when eliminated. In addition, for the analysis of supplemental VC versus gout, Cochran’s Q
258 test showed no heterogeneity in the MR-Egger analysis ($p > 0.05$), and the results of the MR-Egger
259 intercept test indicated that the MR analysis was not affected by horizontal pleiotropy ($p > 0.05$).
260 Leave-one-out sensitivity analysis showed no major SNPs that would greatly affect the results when
261 eliminated, confirming the robustness of the MR results, as shown in Figure 4C.

262 **3.2.3 Reverse MR Analysis of the Causal Relationship Between VC and HUA/Gout**

263 We performed reverse MR analysis to estimate whether VC would affect HUA/gout using SNPs
264 with critical values of $p < 5 \times 10^{-8}$ as IVs. The reverse MR results are shown in Table 6. The results
265 show that there is no reverse causal relationship between absorbed VC and HUA ($p > 0.05$ for all
266 five MR methods). Additionally, there was no reverse causal relationship between supplemental
267 VC and gout ($p > 0.05$ for all five MR methods).

268 Four MR methods exhibited no reverse causal relationship between supplemental VC and HUA ($p >$
269 0.05), whereas two methods showed no reverse causal relationship between pharmacological VC
270 and HUA ($p > 0.05$). Each MR method found no reverse causal relationship between any form of
271 VC and gout ($p > 0.05$).

272 **3.2.4 Reverse MR Sensitivity Analysis**

273 Cochran’s Q test showed no heterogeneity in the reverse MR analysis of absorbed VC and HUA
274 ($p > 0.05$), whereas there may be slight heterogeneity in the reverse MR analysis of supplemental
275 VC and gout ($p = 0.035$). In addition, the MR-Egger intercept test showed that the inverse MR
276 analyses of absorbed VC versus HUA and supplemental VC versus gout were not affected by
277 pleiotropy ($p > 0.05$) (Table 7). Finally, leave-one-out sensitivity analysis confirmed the robustness
278 of the reverse MR results (Supplementary Figures 1 and 2).

279 **4 Discussion**

280 There is evidence from prospective epidemiological studies that dietary factors are clinically
281 associated risk factors for HUA and gout, including evidence for the protective effects of VC (15).

282 Some researchers considered that the urate-lowering effect of VC seemed to be more important
283 than other functions. They further explored the potential mechanism of its urate-lowering properties
284 and found that VC may reduce urate-induced inflammation by inhibiting the activation of the
285 NLRP3 inflammasome (16). Additionally, in vivo studies showed that the VC transporter SVCT1
286 acts as a urate importer and that SVCT1 damage can lower serum uric acid levels (17). However,
287 studies that confirm the relationship between dietary VC intake, serum uric acid concentration, and
288 gout are lacking.

289 In this study, we used data from the 2007–2018 NHANES cross-sectional survey and performed
290 bi-directional MR analysis to accurately investigate the relationship between gout/HUA risks and
291 dietary VC intake levels. The results show that gout/HUA and VC intake are negatively correlated
292 in the cross-sectional survey. Restricted cubic spline analysis showed that daily dietary intakes of
293 75–525 mg and 75–225 mg VC have protective effects on patients with HUA and gout, respectively.
294 In the MR analysis, the causal association between absorbed VC and HUA, as well as supplemental
295 VC and gout was consistent with the cross-sectional study.

296 Consistent with the present study, the dietary and nutritional factors associated with HUA in the
297 Seventh Korean NHANES showed that dietary fibre intake and VC intake were negatively
298 correlated with HUA (18). Another case-control study on the association between diet/obesity and
299 gout in Taiwan showed that low VC intake increased the risk of gout and that increasing food
300 sources rich in VC and dietary fibre can prevent gout (19). A meta-analysis of randomised
301 controlled trials showed that a median supplementary VC dose of 8 mg/day for at least one week
302 significantly decreased HUA (20). In contrast, current clinical dietary interventions that can reduce
303 the frequency of gout flares (e.g. VC supplementation) can reduce serum uric acid levels and be
304 used as adjuncts for urate-lowering treatment, a non-pharmacological approach to treat gout and
305 HUA (21).

306 However, further research shows that in patients with gout, continuous VC treatment for eight
307 weeks did not obviously lower uric acid levels, whether this constituted VC alone (500 mg/d) or
308 VC combined with allopurinol. The results of this study may be biased due to a variety of factors
309 such as dose, participants, and course of treatment (22). Overall, neither clinical observational
310 studies nor randomised controlled trial meta-analyses can control for confounding factors and bias.
311 Furthermore, most clinical studies are small-scale randomised controlled trials, which cannot
312 control the accuracy of the results. Additionally, interventional studies of dietary VC intake levels
313 and HUA/gout are still lacking, necessitating further research.

314 MR analysis can appropriately supplement deficiencies when using a large-sample GWAS database
315 without fixed periods and can predict the permanent effects of VC intake. As the current database
316 did not have data related to dietary VC intake, in the present study, it was important to use MR to
317 explore the causal relationship between the risk of HUA/gout and supplemental VC,
318 pharmacological VC, and ascorbic acid, respectively. In the MR results, the genetic susceptibility
319 of absorbed VC with HUA and supplemental VC with gout is not coincidental; forward analysis
320 and reverse MR testing also supported these negative correlations. The potential mechanisms of
321 action underlying these effects of VC can include the following.

322 First, a gene mutation during the evolution of humans and guinea pigs means that endogenous VC
323 cannot be produced. In addition, VC maintains homeostasis through anti-oxidation and cofactor
324 functions. Blood lacks VC and easily undergoes oxidative stress and peroxide damage, but humans
325 and guinea pigs need endogenous supplementation (23, 24). Second, the most important

326 physiological process in which VC is involved is anti-oxidation. According to research findings,
327 another genetic mutation has been discovered in humans, leading to the elimination of the active
328 uricase gene. This gene can counteract VC deficiency by increasing serum uric acid levels. High
329 intracellular uric acid levels are prone to inducing oxidative stress in the body, and VC reduces the
330 production of mitochondrial Reactive Oxygen Species, increases the level of antioxidant enzymes,
331 and enhances the ability of the body to dissolve uric acid and promote uric acid efflux (25).
332 However, the VC transporter protein modifies the function and activity of URAT1 in proximal renal
333 tubular cells, thus increasing urate excretion in the body. As the body may obtain more fructose
334 than other nutrients during VC intake, the role of VC; however, it will increase the level of uric
335 acid, gout risk, and thus has obvious limitations. A side-by-side study evaluating dietary factors and
336 biochemical indices of patients with gout and asymptomatic HUA confirmed that serum uric acid
337 levels are influenced by dietary factors, and that VC intake in the healthy group was lower than in
338 the disease group. This suggests that dietary intake of energy, protein, and fructose also affects gout
339 and HUA (26). The lack of a significant correlation of supplements: vitamin C and medication:
340 vitamin C with the risk of HUA, and vitamin C absorbed and medication: vitamin C with the risk
341 of gout in the MR study could be attributed to these factors.

342 There are several distinct advantages to the present study. First, not only did this study utilise the
343 NHANES database spanning the longest period, 2007–2018, for data completeness, but it also
344 allowed for an investigation of the association between dietary VC intake and gout/HUA at the
345 epidemiological level. Second, we introduced bi-directional MR analysis, which can address
346 unavoidable influencing factors, such as reverse causality, measurement error, and residual
347 confounders, which exist in ordinary epidemiological studies as well as NHANES data analysis;
348 this adds practical significance to this study. One of the key aspects of this study is its inclusive
349 examination of both gout and HUA, deviating from the conventional approach of focusing solely
350 on a single factor, thus facilitating a more comprehensive investigation of the complexity of this
351 type of immune disease. It facilitated the comparison between each disease to provide more
352 informed advice based on patients in the clinic, as well as experimental direction for researchers to
353 conduct further in vivo and in vitro studies. However, certain limitations exist, including the reliance
354 solely on screening and analysis from the intrinsic database and the absence of extensive, prolonged
355 multi-centre clinical research involving a larger sample size. Further research is required to validate
356 the findings through long-term observational and interventional studies.

357 In conclusion, our study supports a causal relationship between dietary VC intake and the risk of
358 HUA, with cross-sectional studies as well as a portion of our MR analyses suggesting a significant
359 negative association. However, despite observational studies suggesting a negative association,
360 other MR analysis did not yield significant results, suggesting that the results might still be
361 influenced by uncontrollable confounding factors. Therefore, based on our findings, we hypothesise
362 that daily dietary VC intake doses of 75–525 mg and 75–225 mg may potentially decrease the risk
363 of HUA and gout, respectively; however, further studies with larger sample sizes are necessary to
364 confirm these findings.

365 **5 Abbreviations**

366 GWAS, genome-wide association study; HUA, hyperuricemia; IV, instrumental variable; IVW,
367 inverse variance weighting; MR, Mendelian randomisation; NHANES, National Health and
368 Nutrition Examination Survey; SNP, single nucleotide polymorphism; VC, vitamin C

369 **6 Conflict of Interest**

370 The authors declare that the research was conducted in the absence of any commercial or financial
371 relationships that could be construed as a potential conflict of interest.

372 **7 Author Contributions**

373 Z-NP and X-QW conceptualized the study, analyzed and interpreted the data, and revised and edited
374 the manuscript. QD, W-TY, W-QZ, Y-BP, NL, J-YP and L-LG drafted the manuscript. NL, J-YP
375 QD, W-TY and W-QZ provided advice for the project. NL, J-YP and L-LG provided administrative
376 support. All authors read and approved the final manuscript.

377 **8 Funding**

378 This work was supported by the National Natural Science Foundation of China (81960863 and
379 82160901), Construction Project of Yunnan Provincial Fund for Medical Research Center
380 (202102AA310006), Construction Project of National Traditional Chinese Medicine Clinical
381 Research Base (2018 No. 131), Construction Project for the Focal Branch of National Traditional
382 Chinese Medicine (2023 No. 85), The Expert Workstation of Zhangxuan in Yunnan Province
383 (202305AF150175), Funding of Yunnan Applied Basic Research Projects-Union Applied Basic
384 Research Projects-Union Foundation (2019FF002[-082], 2019FF002[-031], 202101AZ070001-
385 072 and 202101AZ070001-074), and Yunnan Provincial Traditional Chinese Medicine Discipline
386 Reserve Talent Training Project (2021 No. 01).

387 **9 Acknowledgments**

388 The authors wish to acknowledge the authors and participants of the involved GWAS for providing
389 summary statistics data.

390 **10 References**

- 391 1. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. *Lancet* (2021) 397:1843-55. doi:
392 10.1016/S0140-6736(21)00569-9
- 393 2. Hansildaar R, Vedder D, Baniaamam M, Tausche A-K, Gerritsen M, Nurmohamed MT.
394 Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. *Lancet Rheumatol*
395 (2021) 3:e58-70. doi: 10.1016/S2665-9913(20)30221-6
- 396 3. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of
397 hyperuricemia. *Am J Transl Res* (2020) 12:3167-81.
- 398 4. Safiri S, Kolahi A-A, Cross M, Hill C, Smith E, Carson-Chahhoud K, et al. Prevalence, deaths,
399 and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories
400 1990-2017. *Arthritis Rheumatol* (2021) 73:702-14. doi: 10.1002/art.41571
- 401 5. Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic
402 hyperuricaemia. *Ann Rheum Dis* (2013) 72:638-45. doi: 10.1136/annrheumdis-2012-202301
- 403 6. Karantas ID, Miliotou AN, Siafaka PI. An updated review for hyperuricemia and gout
404 management; special focus on the available drug delivery systems and clinical trials. *Curr Med*
405 *Chem* (2023) in press. doi: 10.2174/0929867331666230809143758
- 406 7. Grzybowski A, Pietrzak K. Albert Szent-Györgyi (1893-1986): the scientist who discovered
407 vitamin C. *Clin Dermatol* (2013) 31:327-31. doi: 10.1016/j.clindermatol.2012.08.001
- 408 8. Brzezińska O, Styrzyński F, Makowska J, Walczak K. Role of vitamin C in prophylaxis and

409 treatment of gout—A literature review. *Nutrients* (2021) 13:701. doi: 10.3390/nu13020701

410 9. Sun Y, Sun J, Wang J, Gao T, Zhang H, Ma A. Association between vitamin C intake and risk

411 of hyperuricemia in US adults. *Asia Pac J Clin Nutr* (2018) 27:1271-6. doi:

412 10.6133/apjcn.201811_27(6).0014

413 10. Smith GD, Hemani G. Mendelian randomization: genetic anchors for causal inference in

414 epidemiological studies. *Hum Mol Genet* (2014) 23:R89-98. doi: 10.1093/hmg/ddu328

415 11. Lin Z, Chen H, Lan Q, Chen Y, Liao W, Guo X. Composite dietary antioxidant index is

416 negatively associated with hyperuricemia in US adults: An analysis of NHANES 2007-2018. *Int J*

417 *Endocrinol* (2023) 2023:6680229. doi: 10.1155/2023/6680229

418 12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new

419 equation to estimate glomerular filtration rate. *Ann Intern Med* (2009) 150:604-12. doi:

420 10.7326/0003-4819-150-9-200905050-00006

421 13. GWAS to the people. *Nat Med* (2018) 24:1483. doi: 10.1038/s41591-018-0231-3

422 14. Hayes B. Overview of statistical methods for genome-wide association studies (GWAS).

423 *Methods Mol Biol* (2013) 1019:149-69. doi: 10.1007/978-1-62703-447-0_6

424 15. Kuwabara M, Fukuuchi T, Aoki Y, Mizuta E, Ouchi M, Kurajoh M, et al. Exploring the

425 multifaceted nexus of uric acid and health: A review of recent studies on diverse diseases.

426 *Biomolecules* (2023) 13:1519. doi: 10.3390/biom13101519.

427 16. Kim S-K, Choe J-Y, Park K-Y. TXNIP-mediated nuclear factor- κ B signaling pathway and

428 intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome. *Biochem Biophys Res*

429 *Commun* (2019) 511:725-31. doi: 10.1016/j.bbrc.2019.02.141

430 17. Toyoda Y, Miyata H, Uchida N, Morimoto K, Shigesawa R, Kassai H, et al. Vitamin C

431 transporter SVCT1 serves a physiological role as a urate importer: functional analyses and in vivo

432 investigations. *Pflugers Arch* (2023) 475:489-504. doi: 10.1007/s00424-023-02792-1

433 18. So MW, Lim D-H, Kim S-H, Lee S. Dietary and nutritional factors associated with

434 hyperuricemia: The seventh Korean National Health and Nutrition Examination Survey. *Asia Pac J*

435 *Clin Nutr* (2020) 29:609-17. doi: 10.6133/apjcn.202009_29(3).0021

436 19. Lyu L-C, Hsu C-Y, Yeh C-Y, Lee M-S, Huang S-H, Chen C-L. A case-control study of the

437 association of diet and obesity with gout in Taiwan. *Am J Clin Nutr* (2003) 78:690-701. doi:

438 10.1093/ajcn/78.4.690

439 20. Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral vitamin C supplementation on serum

440 uric acid: a meta-analysis of randomized controlled trials. *Arthritis Care Res (Hoboken)* (2011)

441 63:1295-306. doi: 10.1002/acr.20519

442 21. Abhishek A, Doherty M. Education and non-pharmacological approaches for gout.

443 *Rheumatology (Oxford)* (2018) 57:i51-8. doi: 10.1093/rheumatology/kex421

444 22. Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT. Clinically

445 insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot

446 randomized controlled trial. *Arthritis Rheum* (2013) 65:1636-42. doi: 10.1002/art.37925

447 23. Linster CL, Van Schaftingen E. Vitamin C. Biosynthesis, recycling and degradation in

448 mammals. *FEBS J* (2007) 274:1-22. doi: 10.1111/j.1742-4658.2006.05607.x

449 24. Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. *Oral Dis*

450 (2016) 22:463-93. doi: 10.1111/odi.12446

451 25. Li H, Liu X, Lee M-H, Li H. Vitamin C alleviates hyperuricemia nephropathy by reducing

452 inflammation and fibrosis. *J Food Sci* (2021) 86:3265-76. doi: 10.1111/1750-3841.15803

453 26. Türker PF, Hoca M, Özduran G, Ok MA, Çelebi MD. The correlation of uric acid levels with
454 biochemical parameters and dietary factors in individuals with asymptomatic hyperuricemia and
455 gouty arthritis. *Nucleosides Nucleotides Nucleic Acids* (2022) 41:444-62. doi:
456 10.1080/15257770.2022.2051047
457

458 **References**

- 459 [1]N Dalbeth, Gosling A-L, Gaffo A, et al. Gout[J]. *Lancet*, 2021, 397(10287): 1843-1855.
- 460 [2]R Hansildaar, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis:
461 rheumatoid arthritis and gout[J]. *Lancet Rheumatol*, 2021, 3(1): e58-e70.
- 462 [3]L Li, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of
463 hyperuricemia[J]. *Am J Transl Res*, 2020, 12(7): 3167-3181.
- 464 [4]S Safiri, Kolahi A-A, Cross M, et al. Prevalence, Deaths, and Disability-Adjusted Life Years
465 Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017[J]. *Arthritis*
466 *Rheumatol*, 2021, 73(4): 702-714.
- 467 [5]P-V Chowalloor, Keen H-I. A systematic review of ultrasonography in gout and asymptomatic
468 hyperuricaemia[J]. *Ann Rheum Dis*, 2013, 72(5): 638-645.
- 469 [6]I-D Karantas, Miliotou A-N, Siafaka P-I. An updated review for hyperuricemia and gout
470 management; special focus on the available drug delivery systems and clinical trials[J]. *Curr Med*
471 *Chem*, 2023.
- 472 [7]A Grzybowski, Pietrzak K. Albert Szent-Györgyi (1893-1986): the scientist who discovered
473 vitamin C[J]. *Clin Dermatol*, 2013, 31(3): 327-331.
- 474 [8]O Brzezińska, Styrzyński F, Makowska J, et al. Role of Vitamin C in Prophylaxis and Treatment
475 of Gout-A Literature Review[J]. *Nutrients*, 2021, 13(2).
- 476 [9]Y Sun, Sun J, Wang J, et al. Association between vitamin C intake and risk of hyperuricemia
477 in US adults[J]. *Asia Pac J Clin Nutr*, 2018, 27(6): 1271-1276.
- 478 [10]Smith-G Davey, Hemani G. Mendelian randomization: genetic anchors for causal inference in
479 epidemiological studies[J]. *Hum Mol Genet*, 2014, 23(R1): R89-R98.
- 480 [11]Z Lin, Chen H, Lan Q, et al. Composite Dietary Antioxidant Index Is Negatively Associated
481 with Hyperuricemia in US Adults: An Analysis of NHANES 2007-2018[J]. *Int J Endocrinol*, 2023,
482 20236680229.
- 483 [12]A-S Levey, Stevens L-A, Schmid C-H, et al. A new equation to estimate glomerular filtration
484 rate[J]. *Ann Intern Med*, 2009, 150(9): 604-612.
- 485 [13]GWAS to the people[J]. *Nat Med*, 2018, 24(10): 1483.
- 486 [14]B Hayes. Overview of Statistical Methods for Genome-Wide Association Studies (GWAS)[J].
487 *Methods Mol Biol*, 2013, 1019149-169.
- 488 [15]M Kuwabara, Fukuuchi T, Aoki Y, et al. Exploring the Multifaceted Nexus of Uric Acid and
489 Health: A Review of Recent Studies on Diverse Diseases[J]. *Biomolecules*, 2023, 13(10).
- 490 [16]S-K Kim, Choe J-Y, Park K-Y. TXNIP-mediated nuclear factor- κ B signaling pathway and
491 intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome[J]. *Biochem Biophys*
492 *Res Commun*, 2019, 511(4): 725-731.
- 493 [17]Y Toyoda, Miyata H, Uchida N, et al. Vitamin C transporter SVCT1 serves a physiological role
494 as a urate importer: functional analyses and in vivo investigations[J]. *Pflugers Arch*, 2023, 475(4):
495 489-504.

- 496 [18]M-W So, Lim D-H, Kim S-H, et al. Dietary and nutritional factors associated with
497 hyperuricemia: The seventh Korean National Health and Nutrition Examination Survey[J]. *Asia*
498 *Pac J Clin Nutr*, 2020, 29(3): 609-617.
- 499 [19]L-C Lyu, Hsu C-Y, Yeh C-Y, et al. A case-control study of the association of diet and obesity
500 with gout in Taiwan[J]. *Am J Clin Nutr*, 2003, 78(4): 690-701.
- 501 [20]S-P Juraschek, Miller ER-Rd, Gelber A-C. Effect of oral vitamin C supplementation on serum
502 uric acid: a meta-analysis of randomized controlled trials[J]. *Arthritis Care Res (Hoboken)*, 2011,
503 63(9): 1295-1306.
- 504 [21]A Abhishek, Doherty M. Education and non-pharmacological approaches for gout[J].
505 *Rheumatology (Oxford)*, 2018, 57(suppl_1): i51-i58.
- 506 [22]L-K Stamp, O'Donnell J-L, Frampton C, et al. Clinically insignificant effect of supplemental
507 vitamin C on serum urate in patients with gout: a pilot randomized controlled trial[J]. *Arthritis*
508 *Rheum*, 2013, 65(6): 1636-1642.
- 509 [23]C-L Linster, Van Schaftingen E. Vitamin C. Biosynthesis, recycling and degradation in
510 mammals[J]. *FEBS J*, 2007, 274(1): 1-22.
- 511 [24]S-J Padayatty, Levine M. Vitamin C: the known and the unknown and Goldilocks[J]. *Oral Dis*,
512 2016, 22(6): 463-493.
- 513 [25]H Li, Liu X, Lee M-H, et al. Vitamin C alleviates hyperuricemia nephropathy by reducing
514 inflammation and fibrosis[J]. *J Food Sci*, 2021, 86(7): 3265-3276.
- 515 [26]P-F Türker, Hoca M, Özduran G, et al. The correlation of uric acid levels with biochemical
516 parameters and dietary factors in individuals with asymptomatic hyperuricemia and gouty
517 arthritis[J]. *Nucleosides Nucleotides Nucleic Acids*, 2022, 41(5-6): 444-462.

518 **11 Data Availability Statement**

519 The raw data supporting the conclusions of this article will be made available by the authors,
520 without undue reservation.

521 **12 Figure Captions**

522




Figure 1. Study design overview

Note. (A) Flow chart of NHANES 2007-2018 sample selection, (B) General design of the MR Study.




Figure 2. Restricted cubic spline analysis of the association between VC intake and HUA or Gout




Figure 3. MR Effect of vitamin C absorbed on HUA

Note. (A) Scatter plot of SNP-HUA association versus SNP-vitamin C absorbed association; (B) Forest plots of vitamin C absorbed-HUA estimates for each SNP; (C) Leave-one-out sensitivity analysis.

532
533
534
535
536
537




Figure 4. MR Effect of supplements: vitamin C on Gout

Note. (A) Scatter plot of SNP- Gout association versus SNP-vitamin C absorbed association; (B) Forest plots of vitamin C absorbed- Gout estimates for each SNP; (C) Leave-one-out sensitivity analysis.

538
539
540
541

542 **13** Tables

543 **Table 1.** Basic characteristics of participants in the HUA study.

544

Characteristic	N	Overall (N = 192,426,982) ¹	Non-HUA (N = 158,705,924) ¹	HUA (N = 33,721,057) ¹	P-value ²
Age (year)	192,426,982	45.64 ± 16.24	45.00 ± 15.93	48.68 ± 17.26	<0.001
Gender, n (%)	192,426,982				<0.001
Male		92,355,558 (48%)	72,985,306 (46%)	19,370,251 (57%)	
Female		100,071,424 (52%)	85,720,618 (54%)	14,350,806 (43%)	
Race, n (%)	192,426,982				<0.001
Hispanic		30,299,598 (16%)	26,323,148 (17%)	3,976,450 (12%)	
Non-Hispanic white		124,273,125 (65%)	101,950,844 (64%)	22,322,281 (66%)	
Non-Hispanic black		22,028,503 (11%)	17,627,559 (11%)	4,400,944 (13%)	
Other race		15,825,756 (8.2%)	12,804,373 (8.1%)	3,021,383 (9.0%)	
Marital status, n (%)	192,384,707				<0.001
Married		108,477,283 (56%)	90,330,620 (57%)	18,146,663 (54%)	

Characteristic	N	Overall (N = 192,426,982) ¹	Non-HUA (N = 158,705,924) ¹	HUA (N = 33,721,057) ¹	P-value ²
Widowed		8,788,789 (4.6%)	6,439,793 (4.1%)	2,348,996 (7.0%)	
Divorced		19,257,962 (10%)	15,335,326 (9.7%)	3,922,636 (12%)	
Unmarried		55,860,672 (29%)	46,560,485 (29%)	9,300,187 (28%)	
Education Level, n (%)	192,299,382				<0.001
Under high school		29,191,554 (15%)	24,004,393 (15%)	5,187,160 (15%)	
High school or equivalent		44,813,137 (23%)	35,924,420 (23%)	8,888,717 (26%)	
College graduate or above		118,294,691 (62%)	98,659,627 (62%)	19,635,063 (58%)	
Poverty level	179,552,555	2.97 ± 1.66	2.98 ± 1.67	2.91 ± 1.66	0.2
Alcohol, n (%)	184,047,134	101,846,454 (55%)	83,942,947 (55%)	17,903,508 (55%)	0.8
Smoker, n (%)	192,366,786				<0.001
Never		110,972,136 (58%)	92,650,182 (58%)	18,321,954 (54%)	
Former		44,255,187 (23%)	34,632,423 (22%)	9,622,764 (29%)	
Now		37,139,463 (19%)	31,369,386 (20%)	5,770,077 (17%)	

Characteristic	N	Overall (N = 192,426,982) ¹	Non-HUA (N = 158,705,924) ¹	HUA (N = 33,721,057) ¹	P-value ²
BMI	191,205,305	29.12 ± 6.91	28.37 ± 6.51	32.71 ± 7.59	<0.001
Waist (cm)	188,150,185	99.09 ± 16.51	97.16 ± 15.81	108.32 ± 16.66	<0.001
Gout, n (%)	192,426,982				<0.001
Non-gout		187,295,003 (97%)	156,242,184 (NA%)	31,052,819 (NA%)	
Gout		5,131,979 (2.7%)	2,463,740 (NA%)	2,668,239 (NA%)	
CVD, n (%)	192,426,982	13,776,816 (7.2%)	9,868,586 (6.2%)	3,908,230 (12%)	<0.001
Hypertension, n (%)	192,426,982	55,851,108 (29%)	40,155,992 (25%)	15,695,116 (47%)	<0.001
Hyperlipidaemia, n (%)	174,166,347	59,000,325 (34%)	46,126,903 (32%)	12,873,423 (42%)	<0.001
Diabetes, n (%)	192,426,982	16,810,847 (8.7%)	12,361,248 (7.8%)	4,449,599 (13%)	<0.001
Nephrolithiasis, n (%)	192,426,982	17,329,578 (9.0%)	13,753,952 (8.7%)	3,575,625 (11%)	0.006
Creatinine (µmol/L)	192,424,374	77.26 ± 29.87	74.87 ± 27.76	88.51 ± 36.22	<0.001
Serum glucose (mmol/L)	192,426,982	5.48 ± 1.84	5.43 ± 1.84	5.72 ± 1.80	<0.001
eGFR	192,424,374	96.24 ± 21.52	98.38 ± 20.33	86.18 ± 23.96	<0.001

Characteristic	N	Overall (N = 192,426,982) ¹	Non-HUA (N = 158,705,924) ¹	HUA (N = 33,721,057) ¹	P-value ²
Cholesterol (mmol/L)	192,426,982	5.04 ± 1.07	5.01 ± 1.06	5.17 ± 1.12	<0.001
Triglyceride (mmol/L)	192,358,986	1.74 ± 1.44	1.65 ± 1.37	2.17 ± 1.67	<0.001
Direct HDL cholesterol (mmol/L)	192,401,422	1.38 ± 0.42	1.40 ± 0.42	1.26 ± 0.39	<0.001
Uric Acid (umol/L)	192,426,982	322.51 ± 83.91	296.25 ± 62.36	446.10 ± 57.95	<0.001
Vitamin_C (mg)	192,426,982	81.47 ± 74.24	82.93 ± 74.95	74.61 ± 70.36	<0.001
VCQ, n (%)	192,426,982				<0.001
Q1		48,001,038 (25%)	38,120,210 (24%)	9,880,829 (29%)	
Q2		48,269,722 (25%)	40,021,703 (25%)	8,248,019 (24%)	
Q3		48,115,700 (25%)	39,684,899 (25%)	8,430,801 (25%)	
Q4		48,040,521 (25%)	40,879,112 (26%)	7,161,409 (21%)	

545 ¹Mean ± SD or n (%)

546 ²Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott's second-order correction

547 Abbreviations: eGFR, glomerular filtration rate; HUA, hyperuricemia

548

549 **Table 2.** Basic characteristics of participants in the gout study.

550

Characteristic	N	Overall (N = 192,426,982) ¹	Non-gout (N = 187,295,003) ¹	Gout (N = 5,131,979) ¹	P-value ²
Age (year)	192,426,982	45.64 ± 16.24	45.32 ± 16.19	57.55 ± 12.94	<0.001
Gender, n (%)	192,426,982				<0.001
Male		92,355,558 (48.0%)	88,878,925 (47.5%)	3,476,633 (67.7%)	
Female		100,071,424 (52.0%)	98,416,078 (52.5%)	1,655,346 (32.3%)	
Race, n (%)	192,426,982				0.014
Hispanic		30,299,598 (15.7%)	29,834,570 (15.9%)	465,027 (9.1%)	
Non-Hispanic white		124,273,125 (64.6%)	120,723,187 (64.5%)	3,549,938 (69.2%)	
Non-Hispanic black		22,028,503 (11.4%)	21,380,418 (11.4%)	648,085 (12.6%)	
Other race		15,825,756 (8.2%)	15,356,828 (8.2%)	468,928 (9.1%)	
Marital status	192,384,707				<0.001
Married		108,477,283 (56.4%)	105,141,701 (56.1%)	3,335,582 (65.0%)	
Widowed		8,788,789 (4.6%)	8,457,078 (4.5%)	331,711 (6.5%)	

Characteristic	N	Overall (N = 192,426,982) ¹	Non-gout (N = 187,295,003) ¹	Gout (N = 5,131,979) ¹	P-value ²
Divorced		19,257,962 (10.0%)	18,523,213 (9.9%)	734,749 (14.3%)	
Unmarried		55,860,672 (29.0%)	55,133,311 (29.4%)	727,361 (14.2%)	
Education Level, n (%)	192,299,382				0.4
Under high school		29,191,554 (15.2%)	28,298,957 (15.1%)	892,597 (17.4%)	
High school or equivalent		44,813,137 (23.3%)	43,579,805 (23.3%)	1,233,333 (24.0%)	
College graduate or above		118,294,691 (61.5%)	115,288,641 (61.6%)	3,006,049 (58.6%)	
Poverty level	179,552,555	2.97 ± 1.66	2.97 ± 1.66	2.88 ± 1.68	0.4
Alcohol, n (%)	184,047,134	101,846,454 (55.3%)	99,515,325 (55.6%)	2,331,129 (46.8%)	0.006
Smoker, n (%)	192,366,786				<0.001
Never		110,972,136 (57.7%)	108,756,367 (58.1%)	2,215,769 (43.2%)	
Former		44,255,187 (23.0%)	42,344,158 (22.6%)	1,911,029 (37.2%)	
Now		37,139,463 (19.3%)	36,134,283 (19.3%)	1,005,180 (19.6%)	
BMI	191,205,305	29.12 ± 6.91	29.03 ± 6.86	32.61 ± 7.87	<0.001

Characteristic	N	Overall (N = 192,426,982) ¹	Non-gout (N = 187,295,003) ¹	Gout (N = 5,131,979) ¹	P-value ²
Waist (cm)	188,150,185	99.09 ± 16.51	98.79 ± 16.38	110.21 ± 17.41	<0.001
CVD, n (%)	192,426,982	13,776,816 (7.2%)	12,511,132 (6.7%)	1,265,684 (24.7%)	<0.001
Hypertension, n (%)	192,426,982	55,851,108 (29.0%)	52,645,056 (28.1%)	3,206,052 (62.5%)	<0.001
Hyperlipidaemia, n (%)	174,166,347	59,000,325 (33.9%)	56,265,750 (33.2%)	2,734,576 (55.4%)	<0.001
Diabetes, n (%)	192,426,982	16,810,847 (8.7%)	15,648,533 (8.4%)	1,162,314 (22.6%)	<0.001
Nephrolithiasis, n (%)	192,426,982	17,329,578 (9.0%)	16,557,608 (8.8%)	771,969 (15.0%)	<0.001
HUA, n (%)	192,426,982				<0.001
Non-HUA		158,705,924 (82.5%)	156,242,184 (NA%)	2,463,740 (NA%)	
HUA		33,721,057 (17.5%)	31,052,819 (NA%)	2,668,239 (NA%)	
Creatinine (µmol/L)	192,424,374	77.26 ± 29.87	76.69 ± 26.26	97.89 ± 88.64	<0.001
Serum glucose (mmol/L)	192,426,982	5.48 ± 1.84	5.45 ± 1.80	6.43 ± 2.86	<0.001
eGFR	192,424,374	96.24 ± 21.52	96.70 ± 21.32	79.37 ± 22.03	<0.001
Cholesterol (mmol/L)	192,426,982	5.04 ± 1.07	5.03 ± 1.07	5.07 ± 1.18	0.6

Characteristic	N	Overall (N = 192,426,982) ¹	Non-gout (N = 187,295,003) ¹	Gout (N = 5,131,979) ¹	P-value ²
Triglyceride (mmol/L)	192,358,986	1.74 ± 1.44	1.72 ± 1.42	2.35 ± 1.90	<0.001
Direct HDL cholesterol (mmol/L)	192,401,422	1.38 ± 0.42	1.38 ± 0.42	1.23 ± 0.39	<0.001
Uric Acid (umol/L)	192,426,982	322.51 ± 83.91	320.02 ± 81.89	413.28 ± 103.94	<0.001
Vitamin_C (mg)	192,426,982	81.47 ± 74.24	81.81 ± 74.50	69.12 ± 62.74	0.003
VCQ, n (%)	192,426,982				0.2
Q1		48,001,038 (24.9%)	46,523,048 (24.8%)	1,477,991 (28.8%)	
Q2		48,269,722 (25.1%)	46,800,328 (25.0%)	1,469,394 (28.6%)	
Q3		48,115,700 (25.0%)	46,929,892 (25.1%)	1,185,808 (23.1%)	
Q4		48,040,521 (25.0%)	47,041,735 (25.1%)	998,786 (19.5%)	

551 ¹Mean ± SD or n (%)

552 ²Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott's second-order correction

553 Abbreviations: eGFR, glomerular filtration rate; HUA, hyperuricemia

554
555

Table 3. Association between dietary vitamin C levels (quartiles) and HUA or gout.

Disease	Vitamin C						P-value for trend
	Q1	Q2	Q3	Q4			
HUA	Model 1	OR (95% CI)	—	0.80 (0.70–0.91)	0.82 (0.72–0.94)	0.68 (0.59–0.78)	<0.001
		P-value	—	0.001	0.005	<0.001	
	Model 2	OR (95% CI)	—	0.78 (0.68–0.89)	0.81 (0.70–0.93)	0.65 (0.56–0.76)	<0.001
		P-value	—	<0.001	0.004	<0.001	
	Model 3	OR (95% CI)	—	0.81 (0.68–0.96)	0.90 (0.76–1.06)	0.78 (0.65–0.93)	<0.05
		P-value	—	0.014	0.2	0.007	
Gout	Model 1	OR (95% CI)	—	0.99 (0.64–1.52)	0.80 (0.53–1.20)	0.67 (0.46–0.97)	<0.05
		P-value	—	>0.9	0.3	0.034	
	Model 2	OR (95% CI)	—	0.98 (0.63–1.53)	0.74 (0.47–1.16)	0.63 (0.42–0.94)	<0.05
		P-value	—	>0.9	0.2	0.025	
	Model 3	OR (95% CI)	—	1.03 (0.65–1.63)	0.83 (0.52–1.34)	0.77 (0.50–1.20)	>0.05
		P-value	—	0.9	0.4	0.3	

556 Abbreviations: HUA, hyperuricemia

557
558

Table 4. MR results for the causal effect of vitamin C on HUA and gout.

Outcome	Exposure	Method	nSNP	β	SE	OR (95% CI)	P-value
HUA	Vitamin C absorbed	MR-Egger	12	-0.026	0.011	0.974 (0.953–0.996)	0.041
		Weighted median	12	-0.020	0.009	0.980 (0.963–0.998)	0.025
		Inverse variance weighted	12	-0.015	0.006	0.985 (0.973–0.997)	0.015
		Simple mode	12	-0.017	0.016	0.983 (0.954–1.014)	0.313
		Weighted mode	12	-0.021	0.009	0.979 (0.962–0.997)	0.044
HUA	Supplements: vitamin C	MR-Egger	5	3.443	2.730	31.271 (0.148–6,589.606)	0.296
		Weighted median	5	0.045	0.402	1.046 (0.475–2.301)	0.911
		Inverse variance weighted	5	-0.219	0.629	0.803 (0.234–2.755)	0.728
		Simple mode	5	0.468	0.478	1.597 (0.626–4.077)	0.383
		Weighted mode	5	0.299	0.489	1.349 (0.518–3.514)	0.574
HUA	Medication: vitamin C	MR-Egger	4	5.387	3.805	218.551 (0.126–378,799.561)	0.293
		Weighted median	4	-1.047	1.044	0.351 (0.045–2.715)	0.316
		Inverse variance weighted	4	-1.549	1.149	0.213 (0.022–2.022)	0.178
		Simple mode	4	-0.871	1.400	0.418 (0.027–6.507)	0.578
		Weighted mode	4	-0.829	1.342	0.437 (0.031–6.053)	0.580
Gout	Vitamin C absorbed	MR-Egger	13	0.000	0.001	1.000 (0.998–1.003)	0.815
		Weighted median	13	0.001	0.001	1.001 (0.999–1.002)	0.601
		Inverse variance weighted	13	0.001	0.001	1.001 (0.999–1.002)	0.451
		Simple mode	13	0.000	0.002	1.000 (0.997–1.004)	0.822
		Weighted mode	13	0.000	0.001	1.000 (0.999–1.002)	0.686
Gout	Supplements: vitamin C	MR-Egger	6	0.012	0.177	1.012 (0.716–1.431)	0.949
		Weighted median	6	-0.101	0.046	0.904 (0.827–0.988)	0.026
		Inverse variance weighted	6	-0.155	0.037	0.857 (0.797–0.921)	0.000
		Simple mode	6	-0.095	0.065	0.909 (0.800–1.034)	0.207
		Weighted mode	6	-0.095	0.062	0.909 (0.806–1.026)	0.185
Gout	Medication: vitamin C	MR-Egger	4	-0.073	0.468	0.930 (0.372–2.327)	0.891

C

Weighted median	4	-0.014	0.118	0.986 (0.782–1.244)	0.908
Inverse variance weighted	4	0.020	0.102	1.020 (0.835–1.247)	0.845
Simple mode	4	-0.090	0.171	0.914 (0.654–1.278)	0.637
Weighted mode	4	-0.088	0.188	0.916 (0.633–1.325)	0.673

559 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation

560 **Table 5.** Sensitivity analysis between vitamin C and HUA and gout.

561

Outcome	Exposure	Method	Cochran's Q test			MR-Egger intercept test		
			Q	Q_df	P-value	Intercept	SE	P-value
HUA	Vitamin absorbed	^C MR-Egger	19.749	11	0.049	0.002	0.002	0.153
	Supplements: vitamin C	MR-Egger	12.779	3	0.005	-0.013	0.009	0.264
	Medication: vitamin C	MR-Egger	2.539	2	0.281	-0.011	0.006	0.202
Gout	Vitamin absorbed	^C MR-Egger	4.343	11	0.959	3.33×10^{-5}	1.50×10^{-4}	0.829
	Supplements: vitamin C	MR-Egger	5.076	4	0.280	-5.71×10^{-4}	5.92×10^{-4}	0.389
	Medication: vitamin C	MR-Egger	1.778	2	0.411	1.50×10^{-4}	7.38×10^{-4}	0.858

562 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation

563
564

Table 6. Results for the causal effect of vitamin C on HUA and gout.

Outcome	Exposure	Method	nSNP	β	SE	OR (95% CI)	P-value
Vitamin absorbed	C HUA	MR-Egger	102	-0.082	0.073	0.922 (0.798–1.064)	0.268
		Weighted median	102	-0.057	0.077	0.945 (0.812–1.098)	0.459
		Inverse variance weighted	102	-0.050	0.049	0.951 (0.864–1.048)	0.311
		Simple mode	102	-0.102	0.163	0.903 (0.656–1.242)	0.532
		Weighted mode	102	-0.076	0.068	0.927 (0.811–1.059)	0.269
Supplements: vitamin C	HUA	MR-Egger	338	0.000	0.002	1.000 (0.995–1.004)	0.949
		Weighted median	338	0.001	0.003	1.001 (0.996–1.006)	0.704
		Inverse variance weighted	338	-0.004	0.002	0.996 (0.992–0.999)	0.013
		Simple mode	338	-0.004	0.009	0.996 (0.979–1.012)	0.604
		Weighted mode	338	0.000	0.002	1.000 (0.995–1.005)	0.981
Medication: vitamin C	HUA	MR-Egger	261	0.003	0.002	1.003 (1.000–1.006)	0.044
		Weighted median	261	0.003	0.001	1.003 (1.001–1.006)	0.016
		Inverse variance weighted	261	0.000	0.001	1.000 (0.998–1.002)	0.848
		Simple mode	261	-0.009	0.004	0.991 (0.983–0.999)	0.033
		Weighted mode	261	0.002	0.001	1.002 (1.000–1.005)	0.071
Vitamin absorbed	C Gout	MR-Egger	5	-1.844	1.723	0.158 (0.005–4.638)	0.363
		Weighted median	5	-1.545	1.222	0.213 (0.019–2.340)	0.206
		Inverse variance weighted	5	-1.378	1.195	0.252 (0.024–2.626)	0.249
		Simple mode	5	-0.999	2.919	0.368 (0.001–112.413)	0.749
		Weighted mode	5	-1.577	1.247	0.207 (0.018–2.378)	0.275
Supplements: vitamin C	Gout	MR-Egger	12	-0.624	0.560	0.536 (0.179–1.606)	0.291
		Weighted median	12	-0.195	0.177	0.823 (0.582–1.163)	0.269
		Inverse variance weighted	12	-0.195	0.170	0.823 (0.589–1.149)	0.252
		Simple mode	12	-0.157	0.236	0.854 (0.538–1.358)	0.519

Medication: vitamin C	Gout	Weighted mode	12	-0.137	0.226	0.872 (0.560–1.358)	0.556
		MR-Egger	10	-0.497	0.430	0.609 (0.262–1.415)	0.282
		Weighted median	10	-0.033	0.077	0.968 (0.833–1.125)	0.668
		Inverse variance weighted	10	0.019	0.076	1.020 (0.878–1.183)	0.799
		Simple mode	10	-0.122	0.132	0.885 (0.683–1.147)	0.380
		Weighted mode	10	-0.122	0.141	0.885 (0.671–1.167)	0.409

565
566

Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation

567 **Table 7.** Sensitivity analysis between vitamin C and HUA and gout.

568

Outcome	Exposure	Method	Cochran's Q test			MR-Egger intercept test		
			Q	Q df	P-value	Intercept	SE	P-value
Vitamin absorbed	C HUA	MR-Egger	15.422	100	1.000	1.13×10^{-3}	0.002	0.560
Supplements: vitamin C		MR-Egger	392.890	336	0.018	-1.62×10^{-4}	6.15×10^{-5}	0.009
Medication: vitamin C		MR-Egger	298.481	259	0.046	-7.30×10^{-5}	3.12×10^{-5}	0.020
Vitamin absorbed	C Gout	MR-Egger	0.386	3	0.943	0.004	0.011	0.732
Supplements: vitamin C		MR-Egger	19.467	10	0.035	7.59×10^{-4}	9.43×10^{-4}	0.440
Medication: vitamin C		MR-Egger	15.426	8	0.051	8.18×10^{-4}	6.72×10^{-4}	0.258

569 Abbreviations: HUA, hyperuricemia; MR, Mendelian randomisation